Massive Bio, Inc., a NYC-based company that leverages precision medicine and artificial intelligence (AI) to enable patient centric clinical trial enrollment, raised $2.6m in funding.
The round, which brings total funding since launch to $6.6m, was led by Revo Capital with participation from Cavendish Impact Foundation (CIF), through their donor advised fund at ImpactAssets.
The company intends to use the funds to scale to meet the demand in the U.S. and overseas for its oncology clinical trial recruitment platform solutions.
Led by Co-founder and CEO Selin Kurnaz, Massive Bio is an Artificial Intelligence (AI)-driven platform connecting cancer patients and their community oncologists to bio-pharmaceutical clinical trials yielding profound improvement in access and match rates, leading to faster drug development timelines and creating novel oncology data ecosystem for improved protocol design and real-world insights. The company controls patient enrollment value chain starting patient identification, following with AI based virtual pre-screening outside the site and resolving last mile issues for clinical trial enrollment. Massive Bio serves close to two dozen pharmaceutical companies and contract research organizations (CROs) and provides patient recruitment, site selection and real-world data services in oncology.
FinSMEs
03/11/2020